SCHEMBL15034136

SCHEMBL15034136

COC(C)c1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4ccccc4)n3)C(C)(C)C2)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.40
MAPT P10636 11/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
TP53 P04637 4/20 0.37
POLB P06746 4/20 0.37
USP2 O75604 3/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HPGD P15428 2/20 0.34
ABL1 P00519 1/20 0.33
BCR P11274 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ALDH1A1 P00352 2/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020047 0.91 HPGD (0.41) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034152 0.91 MAPT (0.39) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034148 0.86 MEN1 (0.47) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034139 0.86 ALDH1A1 (0.47) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034134 0.85 CFTR (0.44) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034138 0.85 HPGD (0.44) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15034131 0.84 CYP3A4 (0.48) SMN1; SMN2USP2TSHRMAPK1HPGD
SCHEMBL15020006 0.84 ALDH1A1 (0.44) MAPTSMN1; SMN2TP53POLBHPGD
SCHEMBL15034142 0.84 SLC16A3 (0.40) CFTRMAPTSMN1; SMN2TP53POLB
SCHEMBL15020249 0.84 HPGD (0.40) SMN1; SMN2LMNATSHRHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 CFTR 3753/4885MAPT 270/4885SMN1; SMN2 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.